Introducing ACTX 101, a Gene Therapy for Rett Using X Reactivation Technology | RSRT

Traditional gene therapy delivers healthy genes to compensate for mutated ones. During this webinar you will learn about a novel gene therapy approach, ACTX-101 being developed for Rett Syndrome by Alcyone Therapeutics. Rather than deliver a gene, ACTX-101 is designed to reactivate the inactive X chromosome which includes the MECP2 gene. Dr. Sanchita Bhatnagar and Dr. Kathrin Meyer are the scientists behind ACTX-101. They are joined by Dr. Bryn Martin, of Alcyone Therapeutics. Watch and learn about this exciting new strategy to attack Rett Syndrome.

---------------------------------
The Rett Syndrome Research Trust is singularly focused on a cure for Rett syndrome. Achieving success takes a deep understanding of the relevant science, an environment built for scientific collaboration, and experience with drug and business development. Today we are building on incredible scientific and industry momentum by implementing six genetic-based strategies that tackle Rett from every angle. Every single company pursuing a cure for Rett is able to do so because they leveraged discoveries and resources that were generated with RSRT funding. RSRT is the home of the Rett cure community, and we are confident that together we will cure Rett syndrome.